Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-09-25
2007-09-25
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
09578453
ABSTRACT:
The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.
REFERENCES:
patent: 5087617 (1992-02-01), Smith
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5532220 (1996-07-01), Lee et al.
patent: 5565334 (1996-10-01), Kufe et al.
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 5641749 (1997-06-01), Yan et al.
patent: 5641750 (1997-06-01), Louis
patent: 5672344 (1997-09-01), Kelley et al.
patent: 5700657 (1997-12-01), Beaudry et al.
patent: 5716826 (1998-02-01), Gruber et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 6017524 (2000-01-01), Roth et al.
patent: 6261834 (2001-07-01), Srivastava
patent: WO91 18088 (1991-11-01), None
patent: WO92 05272 (1992-04-01), None
patent: WO92 19732 (1992-11-01), None
Moberg et al. Wild-type murine p53 represses transcription from the murinec-mycpromoter in a human glial cell line 1992,pp. 208-215.
Rudinger J in Peptide Hormones. Editor Parsons JA. pp. 1-7, 1976, University Park Press, Baltimore.
Bowie et al., 1990. Science, vol. 247, pp. 1306-1310, especially p. 1306, col. 2, paragraph 2.
Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merzer (ed.), pp. 433&492-495.
Sherman . Annals of NY Acad. Sci. 616:201-204, 1990.
Rojanasakul . Advanced Drug Delivery Reviews 18:115-131, 1996.
Geller J. Neurosci Methods 36:91-103, 1991.
Carter BJ. Curr. Opin Biotechnology. 3:533-539, 1992.
Hulla et al. Nucleic Acid Research 1993: 713-7.
McGarry PNAS 1986, 83:399-403.
Friedman et al., “The p53 protein is an unusually shaped tetramer that binds directly to DNA,”Proceedings of the National Academy of Sciences, vol. 90, No. 8 pp. 3319-3323, Apr. 15, 1993.
Michalovitz et al., “p53 Mutations: gains or losses,”Journal of Cellular Biochemistry, vol. 45, No. 1, p. 25, Jan. 1991.
Kern et al., “Identification of p53 as a sequence-specific DNA-binding protein,”Science, vol. 252, pp. 1708-1711, Jun. 21, 1991.
Bilang-Bleuel et al.,PNAS, vol. 94, pp. 8818-8823, Aug. 1997.
Eizenberg et al.,Molecular and Cellular Biology, vol. 36, No. 9, pp. 5178-5185, Sep. 1996.
Grand et al.,EMBO Journal, vol 5, No. 6, pp. 1253-1260, Jun. 1986.
Fujiiwara et al.,Cancer Research, vol. 53, pp. 4129-4133, Sep. 15, 1993.
Michalovitz et al.,Cell, vol. 62, No. 4, pp. 671-680, Aug. 24, 1990.
Gura,Science, vol. 270, pp. 575-577, Oct. 27, 1995.
Mulligan,Science, vol. 260, pp. 926-930, May 14, 1993.
Orkin & Motulsky, “Report and Recommendations of the Panel to Assess . . . Gene Therapy,” Dec. 7, 1995.
Kremer & Perricaudet,British Medical Bulletin, vol. 51, pp. 31-44, Jan. 1995.
Levrero et al.,Gene, vol. 101, pp. 195-202, 1991.
Funk et al.,Mol. Cell Biology, vol. 12, pp. 2866-2871, Jun. 1992.
Michalovitz et al.,Journal of Cellular Biochemistry, vol. 45, pp. 22-29, Jan. 1991.
Chopp et al.,Biochemical and Biophysical Research Communications, vol. 182, pp. 1201-1207, Feb. 14, 1992.
Soussi et al.,Nucleic Acids Research, vol. 16, p. 11384, 1988.
Roth et al., “Retrovirus-mediated wild-typep53gene transfer to tumors of patients with lung cancer,”Nature Medicine, vol. 2, No. 9, pp. 985-991, Sep. 1996.
Clayman et al., “Gene Therapy for Head and Neck Cancer,”Archives of Otolaryngology-Head&Neck Surgery, pp. 489-493, May 1996.
Clayman et al., “Adeno p53 Gene Transfer ina Phase I/II Trial of Patients with Advanced Recurrent Head and Neck Squmous Carcinoma,”Meeting Update, Society for Biological Therapy: Annual Meting 1996, Sep. 1996.
Abstract No. 2296, Eighty-Eight Annual Meeting, American Association for Cancer Research, Apr. 12-16, 1997, vol. 38—Mar. 1997.
Clayman, et al., “Adenovirus-Mediated p53 Gene Transfer in Patients WithAdvance Recurrent Head and Neck Squamous Cell Carcinoma,”Journal of Clinical Oncology, vol. 16, No. 6, pp. 2221-2232, Jun. 1998.
Le Gal La Salle et al., “An Adenovirus Vector for Gene Transfer into Neurons and Gaila in the Brain,”Science, vol. 259, pp. 988-990, Feb. 12, 1993.
Abstract No. 1363, Program/Proceedings American Society of Clinical Oncology, vol. 16, May 17-20, 1997.
Swisher et al., Abstract, “Adenoviral Mediated p53 Gene Transfer in Patients With Advanced Non-Small Cell Lung Cancer,” p. B-5.
Mallet Jacques
Revah Frederic
Stutzmann Jean-Marie
sanofi-aventis
Whiteman Brian
LandOfFree
Pharmaceutical compositions and utilization thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and utilization thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and utilization thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3792343